Evidence mapPaperPMID 42232021Full record

ArticleFrontiers in global women's health2026

Aligning femtech innovation With equity: a strategic framework for real world impact.

Shirin Ashrafganjouei, Lindsay Eziashi, Muskaan Bhan, Roswitha Priscilla Verwer, Melissa Paola Mezzari

Abstract read
In one paragraph

Article in Frontiers in global women's health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Shirin Ashrafganjouei *YON E Health Innovations B.V., Amsterdam, Netherlands.
Lindsay Eziashi *YON E Health Innovations B.V., Amsterdam, Netherlands.
Muskaan BhanYON E Health Innovations B.V., Amsterdam, Netherlands.
Roswitha Priscilla VerwerYON E Health Innovations B.V., Amsterdam, Netherlands.
Melissa Paola MezzariYON E Health Innovations B.V., Amsterdam, Netherlands.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Femtech is advancing rapidly as a field with the capacity to transform women's health by addressing prevailing inequities in diagnosis, care, and access. Despite systemic, structural, cultural, data, regulatory, and access barriers that have historically limited progress, recent innovations are demonstrating measurable impact. Advances in point of care diagnostics and CRISPR based technologies promise earlier and more precise detection. Wearables and continuous monitoring are expanding opportunities for personalized care, while artificial intelligence, the Internet of Things, and real world data integration are creating new pathways for evidence generation, adaptive decision support, and population level insights. This article synthesizes these developments into a conceptual framework to guide future research, policy, and implementation in femtech, rather than aiming to provide original clinical data. It maps how femtech innovation is reshaping the landscape while highlighting areas where alignment with diverse user needs and infrastructures remains essential. To accelerate translation from innovation to execution, this article proposes a four pillar framework as a strategic roadmap: (1) building inclusive and representative evidence bases, (2) ensuring usability and affordability across contexts, (3) strengthening regulatory and ethical alignment, and (4) fostering integration of data and delivery systems. By situating technological advances within this framework, femtech can become a coherent, equitable, and scientifically robust ecosystem. This evolution holds the potential to close diagnostic and informational gaps and redefine global standards of care. Understanding and addressing these intersecting dimensions will guide research priorities, investment strategies, and policy development, ensuring that femtech fulfills its promise with rigor, inclusivity, and impact.

Indexed as

AI in reproductive healthbarriers in femtechfemtech innovationinclusive health datapoint-of-care testingstrategic framework for femtechwearables and continuous monitoringwomen's health equity

Identifiers

PMID42232021
PMCPMC13222963

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.